Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

X4 Pharmaceuticals (XFOR) Capital Expenditures (2018 - 2025)

X4 Pharmaceuticals (XFOR) has disclosed Capital Expenditures for 7 consecutive years, with $41000.0 as the latest value for Q4 2024.

  • For the quarter ending Q4 2024, Capital Expenditures rose 17.14% year-over-year to $41000.0, compared with a TTM value of $41000.0 through Sep 2025, down 87.19%, and an annual FY2024 reading of $326000.0, up 443.33% over the prior year.
  • Capital Expenditures was $41000.0 for Q4 2024 at X4 Pharmaceuticals, down from $92000.0 in the prior quarter.
  • Across five years, Capital Expenditures topped out at $565000.0 in Q2 2021 and bottomed at $8000.0 in Q2 2023.
  • Average Capital Expenditures over 5 years is $129789.5, with a median of $35000.0 recorded in 2023.
  • The sharpest move saw Capital Expenditures surged 5540.0% in 2020, then plummeted 95.97% in 2021.
  • Year by year, Capital Expenditures stood at $302000.0 in 2020, then tumbled by 95.7% to $13000.0 in 2021, then surged by 161.54% to $34000.0 in 2022, then grew by 2.94% to $35000.0 in 2023, then increased by 17.14% to $41000.0 in 2024.
  • Business Quant data shows Capital Expenditures for XFOR at $41000.0 in Q4 2024, $92000.0 in Q3 2024, and $134000.0 in Q2 2024.